An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00097929
Phase
PHASE2
Status
Completed

Conditions

  • B-cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.

Key Dates

First listed
Dec 2, 2004
Start date
May 1, 2005
Status verified
Apr 2017
Primary completion
Jul 31, 2006
Completion
Jul 31, 2006

Study Design

Enrollment
18 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Objective response rate based on FDG-PET and CT scan findings.

Related Studies